Biopartners terminates collaboration with The Medical House
A supply agreement allowing Swiss-based biopharmaceutical company Biopartners to license and supply a delivery system developed by The Medical House has been terminated due to poor product functionality.
A supply agreement allowing Swiss-based biopharmaceutical company Biopartners to license and supply a delivery system developed by The Medical House has been terminated due to poor product functionality.
The Medical House's GH1 - a reusable, spring powered, needle-free system was selected as part of a 10-year deal in February 2005, to deliver Biopartners" human growth hormone product, Valtropin.
In 2006, Biopartners initiated a comparative bioavailability/bioequivalence study in volunteers to assess Valtropin delivered by GH1. The Medical House has never been able to supply Biopartners with the GH1 devices needed to perform this clinical study. Therefore, Biopartners terminated the collaboration.
"Having received EMEA approval in April 2006, we had planned to launch Valtropin at the end of that year," said Jean-Noel Treilles, Biopartners ceo. "However, with the GH1 device not functioning correctly, we have had to end our agreement with The Medical House in order to seek a suitable and robust alternative delivery system."